

# Procter & Gamble, Co. Presentation to the Celani fund

Sebastian Schisel | April 5, 2021

## Recommendation: Buy

#### 13.73% 12-Month Total Return

(11.40% upside with 2.34% dividend yield)

#### **P&G Market Data**

Market cap (\$mm): 336,740 | P/E Ratio: 22.1

| Buy                   |        |  |  |  |  |
|-----------------------|--------|--|--|--|--|
| Current Price         | 135.45 |  |  |  |  |
| 12-Month Target Price | 150.89 |  |  |  |  |
| Upside                | 11.40% |  |  |  |  |
| Dividend Yield        | 2.34%  |  |  |  |  |
| Total Return          | 13.73% |  |  |  |  |

| Market Data           |         |
|-----------------------|---------|
| Price, as at 03/31/21 | 135.45  |
| Quarterly Dividend    | 0.7907  |
| Annual Dividend Yield | 2.34%   |
| Market Cap. (\$mm)    | 336,740 |
| P/E Ratio             | 22.1    |
| Beta                  | 0.39    |



The Proctor and Gamble Company (P&G)

- ➤ Originated as a simple soap and candle company in 1837.
- ➤ Provides branded consumer packaged goods in North and Latin America, Europe, the Asia Pacific, Greater China, India, the Middle East, and Africa.
- ➤ P&G has operations in more than 80 countries. Its nearly 300 brands are sold in more than 160 countries.
- ➤ Roughly 90,000 employees worldwide.








Picture Source: Businesswire.com





| Reportable Segments          | Net Sales (1) | % of Net Earnings | Product Categories (Sub-Categories)   | Major Brands  |
|------------------------------|---------------|-------------------|---|---|
| Beauty                       | 19%           | 21%               | Hair Care (Conditioner, Shampoo, Styling Aids, Treatments)  | Head & Shoulders, Herbal Essences, Pantene, Rejoice |
| Deauty                       | 1970          | 2170              | Skin and Personal Care (Antiperspirant and Deodorant, Personal Cleansing, Skin Care)  | Olay, Old Spice, Safeguard, Secret, SK-II           |
| Grooming                     | 9%            | 10%               | Grooming (2) (Shave Care - Female Blades & Razors, Male Blades & Razors, Pre- and Post-Shave Products, Other Shave Care; Appliances)            | Braun, Gillette, Venus                              |
|                              |               |                   | Oral Care (Toothbrushes, Toothpaste, Other Oral Care)   | Crest, Oral-B                                       |
| Health Care                  | 13%           | 12%               | Personal Health Care (Gastrointestinal, Rapid Diagnostics, Respiratory, Vitamins/Minerals/Supplements, Pain Relief, Other Personal Health Care) | Metamucil, Neurobion, Pepto-Bismol, Vicks           |
| Fabric & Home Care           | 33%           | 31%               | Fabric Care (Fabric Enhancers, Laundry Additives, Laundry Detergents)   | Ariel, Downy, Gain, Tide                            |
| Fabric & Home Care           | 33%           | 3170              | Home Care (Air Care, Dish Care, P&G Professional, Surface Care)   | Cascade, Dawn, Fairy, Febreze, Mr. Clean, Swiffer   |
|                              |               |                   | Baby Care (Baby Wipes, Taped Diapers and Pants)   | Luvs, Pampers                                       |
| Baby, Feminine & Family Care | 26%           | 26%               | Feminine Care (Adult Incontinence, Feminine Care)   | Always, Always Discreet, Tampax                     |
|                              |               |                   | Family Care (Paper Towels, Tissues, Toilet Paper)   | Bounty, Charmin, Puffs                              |

<sup>(1)</sup> Percent of Net sales and Net earnings from continuing operations for the year ended June 30, 2020 (excluding results held in Corporate).

<sup>(2)</sup> The Grooming product category is comprised of the Shave Care and Appliances operating segments.

Integrated Growth Strategy

- ➤ Creation of a diverse and successful **portfolio**, maintaining **superiority** in their ability to win consumers, pushing **productivity** in both improvements in operations and ability to fuel investments.
- ➤ Constructive Disruption showing a willingness to change, adapt, and create new trends. Maintaining an agile, empowered, and accountable organization.

Big, Predictable and Profitable Innovation

- ➤ Continued growth and success of existing brands and products, as well as the creation of new innovative products and brands.
- ➤ Value creation for the consumer through high-quality and reasonable prices.

Impact on Sales

- ➤ Net sales increased 8% to \$39.1 billion.
- ➤ Net earnings were \$8.2 billion, an increase of \$835 million or 11% versus the prior year period due to the increase in net sales and an increase in operating margins.

| ORG<br>FY 20      |        | IC SAI                              | <b>.ES</b>                     | 4//                |      |                                     | 8"                             |
|-------------------|--------|-------------------------------------|--------------------------------|--------------------|------|-------------------------------------|--------------------------------|
| Home              | Care   |                                     | +10                            | 6%                 |      |                                     |                                |
| Person            | nal He | alth Care                           | +13                            | 3%                 |      |                                     |                                |
| Family            | Care   |                                     | +1                             | %                  |      | 10                                  |                                |
| Fabric            | Care   |                                     | +7                             | 7%                 | 9    | of 10                               |                                |
| Femin             |        |                                     |                                |                    | CATE | GORIES                              |                                |
| Skin a<br>Hair C  |        | rsonal Care                         |                                | 5%                 |      | KEW                                 |                                |
| Oral C            |        |                                     | +4                             | 1%                 |      |                                     |                                |
| PaG               |        |                                     |                                |                    |      |                                     |                                |
| P&G<br>Brand      | Rank   | U.S.<br>Market Share <sup>(1)</sup> | P&G Share vs.<br>#2 Competitor | P&G<br>Brand       | Rank | U.S.<br>Market Share <sup>(1)</sup> | P&G Share vs.<br>#2 Competitor |
| always            | #1     | 54%                                 | 3.0x                           | Downy              | #1   | 40%                                 | 3.0x                           |
| and the same of   |        |                                     |                                |                    |      |                                     |                                |
| Bounty            | #1     | 44%                                 | 5.5x                           | Gillette           | #1   | 66%                                 | 5.0x                           |
| Bounty<br>Cascade | #1     | 44%<br>64%                          | 5.5x<br>3.0x                   | Gillette<br>Oral B | #1   | 66%<br>34%                          | 5.0x<br>2.0x                   |
| 10                |        |                                     |                                |                    | #1   |                                     |                                |
| Cascade           | #1     | 64%                                 | 3.0x                           | Oral B             | #1   | 34%                                 | 2.0x                           |

| Three Months Ended December 31, 2020 | Net Sales Growth | Foreign Exchange Impact | Acquisition & Divestiture Impact/Other (1) | Organic Sales Growth |
|--------------------------------------|------------------|-------------------------|--|----------------------|
| Beauty                               | 6%               | (1)%                    | -%   | 5%                   |
| Grooming                             | 5%               | 1%                      | —%   | 6%                   |
| Health Care                          | 9%               | —%                      | —%   | 9%                   |
| Fabric & Home Care                   | 12%              | %                       | —%   | 12%                  |
| Baby, Feminine & Family Care         | 6%               | —%                      | <del>-</del> %                             | 6%                   |
| Total Company                        | 8%               | —%                      | <u>_%</u>                                  | 8%                   |

<sup>(1)</sup> Acquisitions/Divestiture impact/Other includes the volume and mix impact of acquisitions and divestitures and rounding impacts necessary to reconcile net sales to organic sales.

| Liquidity Ratios        |      | Efficiency        |        | Financial Leverage       |       | Profitability                 |       | Growth and valuation             |        | Activity Ratio               |        |
|-------------------------|------|-------------------|--------|--------------------------|-------|-------------------------------|-------|----------------------------------|--------|------------------------------|--------|
| Cash ratio              | 0.49 | Days receivables  | 21.49  | Debt to total assets     | 0.29  | Return on common equity (ROE) | 28.0% | One-year sales growth            | 4.6%   | Asset turnover               | 0.59   |
| Acid test (Quick ratio) | 0.62 | Days payables     | 124.99 | Leverage Ratio           | 1.57  | Return on assets              | 8.6%  | One-year operating income growth | 65.1%  | Accounts receivable turnover | 16.98  |
| Current ratio           | 0.85 | Days of inventory | 56.93  | Long-term leverage ratio | 0.50  | Return on invested capital    | 12.6% | One-year net income growth       | 69.73% | Inventory turnover           | 6.41   |
|                         |      |                   |        | Debt to Equity           | 0.74  | Gross margin                  | 50.3% | Enterprise multiple              | 17.5   | Cash conversion cycle (days) | (46.57 |
|                         |      |                   |        | Total debt to EBITDA     | 1.85  | EBITDA Margin                 | 26.4% | Enterprise value-to-sales        | 4.6    |                              |        |
|                         |      |                   |        | Interest cover ratio     | 33.78 | Operating margin              | 22.1% | P/E ratio                        | 22.9   |                              |        |
|                         |      |                   |        |                          |       | Pre-tax margin                | 22.3% |                                  |        |                              |        |
|                         |      |                   |        |                          |       | Net income margin             | 18.5% |                                  |        |                              |        |

#### **Other Key Financial Metrics**

#### **Key Financial Metrics**

- . Growth, Valuation, & Liquidity
  - One-year sales Growth: 4.6%
  - Interest coverage ratio: 33.78
  - . Enterprise value-to-sales: 4.8
- · Dividend Information
  - Div. Yield (LTM): 2.34%
  - DPS: \$3.12
  - DPS 5Y CAGR: 3.44%

- Margins:
  - EBITDA: 26.4%
  - Pre-tax: 22.3%
  - Net Income: 18.5%
- Net Working Capital:
  - Days Payable: 124.99
  - Inventory Turnover: 6.41x
  - Days Receivable: 21.49



## P&G Comparable Analysis

|                                     |                         | COMPARABLE ANALYSIS - L  |                         |                            |                         |
|-------------------------------------|-------------------------|--------------------------|-------------------------|----------------------------|-------------------------|
|                                     | Procter & Gamble (\$PG) | Colgate-Palmolive (\$CL) | Church & Dwight (\$CHD) | The Clorox Company (\$CLX) | Average (Excluding P&G) |
| Market Price, as at Fiscal Year End | 117.46                  | 85.04                    | 86.96                   | 216.05                     | 129.35                  |
| Shares Outstanding                  | 2,486                   | 859                      | 252                     | 128                        | 413                     |
| Market Capitalization               | 292,016                 | 73,075                   | 21,931                  | 27,583                     | 40,863                  |
| Debt                                |                         |                          |                         |                            |                         |
| Short-Term                          | 11,183                  | 267                      | 351                     | 0                          | 206                     |
| Long-Term                           | 23,537                  | 7334                     | 1,813                   | 2780                       | 3,976                   |
| Total Debt                          | 34,720                  | 7,601                    | 2,164                   | 2,780                      | 4,182                   |
| Enterprise Value                    | 326,736                 | 80,676                   | 24,095                  | 30,363                     | 45,045                  |
| EBIT                                | 15,706                  | 3,885                    | 1,030                   | 1,284                      | 2,066                   |
| Depreciation & Amortization         | 3,013                   | 539                      | 190                     | 180                        | 303                     |
| EBITDA                              | 18,719                  | 4,424                    | 1,219                   | 1,464                      | 2,369                   |
| EBITDA Multiple                     | 17.45                   | 18.24                    | 19.76                   | 20.74                      | 19.58                   |
| Earnings per Share                  | 5.13                    | 3.15                     | 3.18                    | 7.46                       | 4.60                    |
| P/E Ratio, as at Fiscal Year End    | 22.90                   | 27.00                    | 27.35                   | 28.96                      | 27,77                   |
| Procter & Gamble (\$PG)             |                         |                          |                         |                            |                         |
| EBIT                                | 15,706                  | 15,706                   | 15,706                  | 15,706                     | 15,706                  |
| Depreciation & Amortization         | 3,013                   | 3,013                    | 3,013                   | 3,013                      | 3,013                   |
| EBITDA                              | 18,719                  | 18,719                   | 18,719                  | 18,719                     | 18,719                  |
| Enterprise Value                    | 326,736                 | 341,359                  | 369,885                 | 388,232                    | 366,492                 |
| Less: Debt                          | 34,720                  | 34,720                   | 34,720                  | 34,720                     | 34,720                  |
| Equity Value                        | 292,016                 | 306,639                  | 335,165                 | 353,512                    | 331,772                 |
| Shares Outstanding                  | 2,486                   | 2,486                    | 2,486                   | 2,486                      | 2,486                   |
| Value per Share                     | 117.46                  | 123.34                   | 134.82                  | 142.20                     | 133.45                  |
| Price, as at Fiscal YE              | 117.46                  | 117.46                   | 117.46                  | 117.46                     | 117.46                  |
| Under (Over) Valued (%)             | 0%                      | 5%                       | 15%                     | 21%                        | 14%                     |









| FREE CASH FLO                        | WS - USD (\$) in Mi | llions |        |        |        |
|--------------------------------------|---------------------|--------|--------|--------|--------|
| Discounted Cash Flow Model           | 2021E               | 2022E  | 2023E  | 2024E  | 2025E  |
| Operating Earnings                   | 16,570              | 17,315 | 17,825 | 18,201 | 18,585 |
| Less: Taxes                          | 25.97%              | 25.97% | 25.97% | 25.97% | 25.97% |
| Net Operating Profit After Taxes     | 12,267              | 12,819 | 13,196 | 13,475 | 13,759 |
| Less: CAPEX, Net                     | (1,195)             | (905)  | (661)  | (589)  | (561)  |
| Net Working Capital Changes          | 549                 | 474    | 324    | 239    | 244    |
| Free Cash Flow                       | 11,621              | 12,389 | 12,859 | 13,125 | 13,442 |
| Weighted Average Cost of Capital     | 3.45%               |        |        |        |        |
| Net Present Value of Free Cash Flows | \$57,231            |        |        |        |        |

#### **Additional Valuation Information**

- ➤ NOPAT calculated using tax rate averaged from 2018-2020.
  - This was an increase from PY of 8.7%.
- ➤ CAPEX based on predetermined purchase orders found in 10-K and tied to sales.

| Long-Term Growth Rate  |   |
|--|---|
| Net Reinvestment   |   |
| CAPEX & Depreciation   | 561   |
| NWC Changes  | (244  |
| Net Reinvestment   | 317   |
| NOPAT  | 13,759  |
| Net Reinvestment Rate  | 2.319   |
| Return on Invested Capital   |   |
| NOPAT  | 13,759  |
| Invested Capital   | 114,482   |
| ROIC   | 12.029  |
| Long-Term Growth Rate  | 0.289   |
| Long-Term Growth Rate  | 0.289   |
| Long-Term Growth Rate<br>Terminal Value  | 0.289   |
| Terminal Value<br>Numerator  | 14,042  |
| Terminal Value  Numerator  Denominator   | 14,042<br>3.179   |
| Terminal Value<br>Numerator  | 14,042  |
| Terminal Value  Numerator  Denominator   | 14,042<br>3.179   |
| Terminal Value  Numerator  Denominator  Terminal Value   | 14,042<br>3.179<br>442,732  |
| Terminal Value  Numerator  Denominator  Terminal Value  Present Value of Terminal Value  | 14,042<br>3.179<br>442,732<br>373,693   |
| Terminal Value  Numerator  Denominator  Terminal Value  Present Value of Terminal Value  Enterprise Value  | 14,042<br>3.179<br>442,732<br>373,693<br>430,924  |
| Terminal Value  Numerator  Denominator  Terminal Value  Present Value of Terminal Value  Enterprise Value Less: Net Debt  Add: Short-Term Investments  | 14,042<br>3.179<br>442,732<br>373,693<br>430,924<br>34,720                                    |
| Terminal Value  Numerator  Denominator  Terminal Value  Present Value of Terminal Value  Enterprise Value Less: Net Debt Add: Short-Term Investments  Equity Value   | 14,042<br>3.179<br>442,732<br>373,693<br>430,924<br>34,720                                    |
| Terminal Value  Numerator  Denominator  Terminal Value  Present Value of Terminal Value  Enterprise Value Less: Net Debt  Add: Short-Term Investments  | 14,042<br>3.179<br>442,732<br>373,693<br>430,924<br>34,720                                    |
| Terminal Value  Numerator  Denominator  Terminal Value  Present Value of Terminal Value  Enterprise Value Less: Net Debt Add: Short-Term Investments  Equity Value Diluted Weighted Average Common Shares Outstanding Value per Share  | 14,042<br>3.179<br>442,732<br>373,693<br>430,924<br>34,720<br>-<br>396,204<br>2,626<br>150.88 |
| Terminal Value  Numerator  Denominator  Terminal Value  Present Value of Terminal Value  Enterprise Value Less: Net Debt Add: Short-Term Investments  Equity Value Diluted Weighted Average Common Shares Outstanding Value per Share  Market Price, as at date of 10-K (06/30/2020) | 14,042<br>3.179<br>442,732<br>373,693<br>430,924<br>34,720<br>396,204<br>2,626<br>150.89      |
| Terminal Value  Numerator  Denominator  Terminal Value  Present Value of Terminal Value  Enterprise Value Less: Net Debt Add: Short-Term Investments  Equity Value  Diluted Weighted Average Common Shares Outstanding   | 14,042<br>3.179<br>442,732<br>373,693<br>430,924<br>34,720<br>-<br>396,204<br>2,626<br>150.88 |
| Terminal Value  Numerator Denominator Terminal Value  Present Value of Terminal Value  Enterprise Value Less: Net Debt Add: Short-Term Investments  Equity Value Diluted Weighted Average Common Shares Outstanding Value per Share  Market Price, as at date of 10-K (06/30/2020)   | 14,042<br>3.179<br>442,732<br>373,693<br>430,924<br>34,720<br>396,204<br>2,626<br>150.89      |

## DCF Target:

DCF Target: \$150.89 (11.40% upside)


WACC: 3.45%

Terminal Growth: 0.28%

|           | Weighted Average Cost of Capital |        |        |        |        |       |  |  |
|-----------|----------------------------------|--------|--------|--------|--------|-------|--|--|
|           | 150.89                           | 1.50%  | 2.50%  | 3.45%  | 4.50%  | 5.50% |  |  |
| Rate      | 0.75%                            | 674.85 | 280.55 | 176.62 | 122.90 | 93.88 |  |  |
| h Ra      | 0.50%                            | 507.37 | 246.04 | 161.99 | 115.44 | 89.35 |  |  |
| LT-Growth | 0.28%                            | 415.77 | 221.81 | 150.89 | 109.54 | 85.67 |  |  |
| Ģ         | 0.10%                            | 363.81 | 205.78 | 143.13 | 105.28 | 82.97 |  |  |
| 17        | 0.05%                            | 351.43 | 201.67 | 141.08 | 104.14 | 82.24 |  |  |


Correlation and Performance

- Considering a 5-year monthly beta of 0.39 P&G tends to follow overall market trends, but with a lesser degree of volatility in price swings.
- ➤ The 2.5-year CAGR for P&G is 24.52%.
- ➤ The 2.5-year CAGR for the S&P 500 is 15.15%.
- Consistent dividends in addition to muted lows helps provide solid returns and even a potential hedging opportunity for investors.



■YETI ■S&P 500

#### P&G vs. The S&P 500





### Investment Risks

- > Business results depend on their ability to manage disruptions in their global supply chain.
- Reliance on third parties in many aspects of their business creates additional risk.
- > Disruptions in credit markets or changes to their credit ratings may reduce their access to credit.
  - Currently holding an AA- long-term credit rating from Standard & Poor's with a stable outlook.

#### **Supply Chain Management**





- P&G supply chain ranked among top five "Supply Chain Masters" by Gartner.
- Rapid Response system created by Kinaxis to assist in real-time supply chain management.

### Conclusion & Recommendation

### P&G

| Current/Proposed Portfolio Information         |               |  |  |  |
|--|---------------|--|--|--|
| Current Position (P&G)                         | \$19,685.87   |  |  |  |
| Current Portfolio Weighting                    | 0.77%         |  |  |  |
| Current Industry Weighting (Consumer Staples)  | 2.54%         |  |  |  |
| Proposed Position                              | ~\$100,000.00 |  |  |  |
| Proposed Industry Weighting (Consumer Staples) | ~5.50%        |  |  |  |

| Buy                   |        |  |  |  |  |
|-----------------------|--------|--|--|--|--|
| Current Price         | 135.45 |  |  |  |  |
| 12-Month Target Price | 150.89 |  |  |  |  |
| Upside                | 11.40% |  |  |  |  |
| Dividend Yield        | 2.34%  |  |  |  |  |
| Total Return          | 13.73% |  |  |  |  |



Investment Recommendation: Buy \$80,000 of PG

- P&G's low beta will assist in achieving an improved Treynor and Sharpe ratio for our overall portfolio metrics.
- P&G provides consistent and regularly increasing dividend income in addition to the potential 11.40% upside of the stock price.
- Median 12-month target estimates from many other analysts result in an anticipated price of \$150.88-\$154.00.

#### **Exit Strategy (Barring Abnormal Market Movement)**

In April 2022, if P&G has a price per share of \$105.30 or lower (10% under lowest analyst price targets)



In April 2022, if P&G has a price per share of \$183.70 or higher (10% over highest analyst price targets)

### Questions

Celani Fund | April 5, 2021

## Appendix

Celani Fund | April 5, 2021

### Appendix 1: Assumptions

| Assumptions  | Actuals | Projections |            |          |           |         |
|--|---------|-------------|------------|----------|-----------|---------|
| Year   | 2020A   | 2021E       | 2022E      | 2023E    | 2024E     | 2025E   |
| Income Stater  | nent:   |             |            |          |           |         |
| Sales Growth   | 4.83%   | 5.50%       | 4.50%      | 2.94%    | 2.11%     | 2.11%   |
| Gross Margin   | 50.3%   | 50.3%       | 50.3%      | 50.3%    | 50.3%     | 50.3%   |
| Selling, General and Administrative                              | 28.2%   | 28.2%       | 28.2%      | 28.2%    | 28.2%     | 28.2%   |
| Investment Income, Interest (acquisition and divestiture gains)  | 155     | 155         | 155        | 155      | 155       | 155     |
| Other Non-Operating Income                                       | 438     | 438         | 438        | 438      | 438       | 438     |
| Tax Rate   | 17.20%  | 25.97%      | 25.97%     | 25.97%   | 25.97%    | 25.97%  |
| Balance She  | eet:    |             |            |          |           |         |
| Minimum Cash   |         | 4,239       | 4,239      | 4,239    | 4,239     | 4,239   |
| Days Sales Outstanding (DSO)                                     | 21.49   | 21.49       | 21.49      | 21.49    | 21.49     | 21.49   |
| Days Sales Inventory (DSI)                                       | 56.93   | 56.93       | 56.93      | 56.93    | 56.93     | 56.93   |
| Prepaid Expenses (% of Sales)                                    | 3%      | 3%          | 3%         | 3%       | 3%        | 3%      |
| Property, Plant and Equipment, *(Purchases required per purchase |         |             |            |          |           |         |
| agreements and tied to sales - see below for more information)   | 20,692  | 21,887      | 22,792     | 23,453   | 24,042    | 24,603  |
| Liabilities  | i:      |             |            |          |           |         |
| Days Payable Outstanding (DPO)                                   | 124.99  | 124.99      | 124.99     | 124.99   | 124.99    | 124.99  |
| Accrued and Other Liabilities, Current (% of Cost of Sales)      | 27.58%  | 27.58%      | 27.58%     | 27.58%   | 27.58%    | 27.58%  |
| Long-Term Debt   | 23,537  |             |            | Plug-It  |           |         |
| Deferred Income Tax Liabilities, Net                             | 6,199   | 6,199       | 6,199      | 6,199    | 6,199     | 6,199   |
| Other Liabilities, Noncurrent                                    | 11,110  | 11,110      | 11,110     | 11,110   | 11,110    | 11,110  |
| Stockholders' E  | quity:  |             |            |          |           |         |
| Common Stock   | 4,009   | 4,009       | 4,009      | 4,009    | 4,009     | 4,009   |
| Additional Paid in Capital                                       | 64,194  | 64,194      | 64,194     | 64,194   | 64,194    | 64,194  |
| Reserve for ESOP Debt Retirement                                 | (1,080) | (1,080)     | (1,080)    | (1,080)  | (1,080)   | (1,080) |
| Retained Earnings (Accumulated Deficit)                          | 100,239 | Pre         | vious Bala | nce plus | Net Incom | ie      |
| Stockholders' Equity Attributable to Noncontrolling Interest     | 0.36%   | 0.38%       | 0.40%      | 0.42%    | 0.43%     | 0.45%   |

\*Has purchase commitments for materials, supplies, services and property, plant and equipment as part of the normal course of business. Commitments made under take-or-pay obligations are as follows: Such amounts represent minimum commitments under take-or-pay agreements with suppliers and are in line with expected usage. These amounts include purchase commitments related to service contracts for information technology, human resources management and facilities management activities that have been outsourced to third-party suppliers. Due to the proprietary nature of many of our materials and processes, certain supply contracts contain penalty provisions for early termination. We do not expect to incur penalty payments under these provisions that would materially affect our financial position, results of operations or cash flows.

| Year          | 2020   | Year          | 2019   |  |
|---------------|--------|---------------|--------|--|
| Sales Change  | 3,266  | Sales Change  | 852    |  |
| cogs          | 482    | cogs          | 336    |  |
| % Variable    |        | % Variable    | 39.44% |  |
| Variable COGS | 5,202  | Variable COG! | 13,711 |  |
| Fixed COGS    | 30,048 | Fixed COGS    | 21,057 |  |
| Total COGS    | 35,250 | Total COGS    | 34,768 |  |
| SGA Change    | 910    | SGA Change    | 47     |  |
| % Variable    | 28%    | % Variable    | 5.52%  |  |
| Variable SGA  | 5,571  | Variable SGA  | 1,053  |  |
| Fixed SGA     | 14,423 | Fixed SGA     | 18,031 |  |
| Total SGA     | 19,994 | Total SGA     | 19,084 |  |

## Appendix 2: Income Statement Forecast

|   | 2020A     | 2021E     | 2022E     | 2023E     | 2024E     | 2025E     |
|---|-----------|-----------|-----------|-----------|-----------|-----------|
| Income Statement  |           |           |           |           |           |           |
| Net Sales   | \$ 70,950 | \$ 74,852 | \$ 78,221 | \$ 80,520 | \$ 82,219 | \$ 83,954 |
| Cost of Goods Sold (Deprecated 2018-01-31)                      | 35,250    | 37,189    | 38,862    | 40,005    | 40,849    | 41,711    |
| Selling, General and Administrative Expense                     | 19,994    | 21,094    | 22,043    | 22,691    | 23,170    | 23,659    |
| Goodwill & Indefinite Lived Intangible Asset Impairment Charges | 0         | 0         | 0         | 0         | 0         | 0         |
| Operating Income  | 15,706    | 16,570    | 17,315    | 17,825    | 18,201    | 18,585    |
| Interest Expense  | (465)     | (139)     | 0         | 0         | 0         | 0         |
| Investment Income, Interest                                     | 155       | 155       | 155       | 155       | 155       | 155       |
| Other Nonoperating Income (Expense)                             | 438       | 438       | 438       | 438       | 438       | 438       |
| Earnings from Continuing Operations Before Income Taxes         | 15,834    | 17,023    | 17,908    | 18,418    | 18,794    | 19,178    |
| Income Taxes on Continuing Operations                           | 2,731     | 4,420     | 4,650     | 4,782     | 4,880     | 4,980     |
| Net Earnings  | 13,103    | 12,603    | 13,258    | 13,635    | 13,914    | 14,198    |
| Less: Net Earnings Attributable to Noncontrolling Interest      | 76        | 73        | 77        | 79        | 81        | 82        |
| Net Income (Loss) Attributable to Proctor & Gamble              | \$ 13,027 | \$ 12,530 | \$ 13,181 | \$ 13,556 | \$ 13,833 | \$ 14,116 |

## Appendix 3: Balance Sheet Forecast

| CONSOLIDATED BALANCE SHEETS -   | JSD (\$) in Mi | llion | 5         |           |           |           |           |
|---|----------------|-------|-----------|-----------|-----------|-----------|-----------|
|   | 2020A          |       | 2021E     | 2022E     | 2023E     | 2024E     | 2025E     |
| CURRENT ASSETS  |                |       |           |           |           |           |           |
| Cash and cash equivalents   | 16,181         | \$    | 4,239     | \$ 6,241  | \$ 19,539 | \$ 33,103 | \$ 46,984 |
| Available-for-sale Securities   | -              |       | -         | /-        | A.        | - 4       | +         |
| Accounts Receivable, after Allowance for Credit Loss, Current                             | 4,178          |       | 4,408     | 4,606     | 4,742     | 4,842     | 4,944     |
| INVENTORIES   |                |       |           |           |           |           |           |
| Inventory, Raw Materials and Supplies, Gross  | 1,414          |       | 1,492     | 1,559     | 1,605     | 1,639     | 1,673     |
| Inventory, Work in Process, Gross   | 674            |       | 711       | 743       | 765       | 781       | 798       |
| Inventory, Finished Goods, Gross  | 3,410          |       | 3,598     | 3,759     | 3,870     | 3,952     | 4,035     |
| Total Inventories   | 5,498          |       | 5,800     | 6,061     | 6,240     | 6,371     | 6,506     |
| Prepaid Expense and Other Assets, Current   | 2,130          |       | 2,247     | 2,348     | 2,417     | 2,468     | 2,520     |
| Total Assets, Current   | 27,987         |       | 16,694    | 19,257    | 32,938    | 46,784    | 60,954    |
| Property, Plant and Equipment, Net  | 20,692         |       | 21,887    | 22,792    | 23,453    | 24,042    | 24,603    |
| Goodwill  | 39,901         |       | 39,901    | 39,901    | 39,901    | 39,901    | 39,901    |
| Trademarks and Other Intangible Assets, Net (Excluding Goodwill)                          | 23,792         |       | 23,792    | 23,792    | 23,792    | 23,792    | 23,792    |
| Other Assets, Noncurrent  | 8,328          |       | 8,328     | 8,328     | 8,328     | 8,328     | 8,328     |
| Total Assets  | 120,700        | 5     | 110,603   | \$114,070 | \$128,412 | \$142,847 | \$157,578 |
| CURRENT LIABILITIES   |                |       |           |           |           |           |           |
| Accounts Payable, Current   | 12,071         |       | 12,735    | 13,308    | 13,699    | 13,988    | 14,283    |
| Accrued and Other Liabilities, Current  | 9,722          |       | 10,257    | 10,718    | 11,033    | 11,266    | 11,504    |
| Debt, Current   | 11,183         |       |           |           |           |           |           |
| Total Liabilities, Current  | 32,976         |       | 22,992    | 24,026    | 24,733    | 25,254    | 25,787    |
| Long-term Debt, Excluding Current Maturities  | 23,537         |       | 10,825    | -         | -         |           | -         |
| Deferred Income Tax Liabilities, Net  | 6,199          |       | 6,199     | 6,199     | 6,199     | 6,199     | 6,199     |
| Other Liabilities, Noncurrent   | 11,110         |       | 11,110    | 11,110    | 11,110    | 11,110    | 11,110    |
| Total Liabilities   | 73,822         |       | 51,126    | 41,335    | 42,042    | 42,563    | 43,096    |
| SHAREHOLDERS' EQUITY  |                |       |           |           |           |           |           |
| Convertible Class A preferred stock, stated value \$1 per share (600 shares authorized)   | 897            |       | 897       | 897       | 897       | 897       | 897       |
| Non-Voting Class B preferred stock, stated value \$1 per share (200 shares authorized)    |                |       | 4         | -         | -         |           | -         |
| Common stock, stated value \$1 per share (10,000 shares authorized; shares issued: 2020 - | 4,009          |       | 4,009     | 4,009     | 4,009     | 4,009     | 4,009     |
| 4,009.2, 2019 - 4,009.2)  |                |       |           |           |           |           |           |
| Additional Paid in Capital  | 64,194         |       | 64,194    | 64,194    | 64,194    | 64,194    | 64,194    |
| Reserve for ESOP Debt Retirement  | (1,080)        |       | (1,080)   | (1,080)   | (1,080)   | (1,080)   | (1,080)   |
| Accumulated Other Comprehensive Income (Loss), Net of Tax                                 | (16,165)       |       | (16,165)  | (16,165)  | (16,165)  | (16,165)  | (16,165)  |
| Treasury stock, at cost (shares held: 2020 - 1,529.5, 2019 - 1,504.5)                     | (105,573)      |       | (105,573) | (105,573) | (105,573) | (105,573) | (105,573) |
| Retained Earnings (Accumulated Deficit)   | 100,239        |       | 112,765   | 125,946   | 139,502   | 153,335   | 167,451   |
| Stockholders' Equity Attributable to Noncontrolling Interest                              | 357            |       | 430       | 507       | 586       | 667       | 749       |
| Total Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest     | 46,878         |       | 59,477    | 72,735    | 86,370    | 100,284   | 114,482   |
| Total Liabilities and Equity  | 120,700        | \$    | 110,603   | \$114,070 | \$128,412 | \$142,847 | \$157,578 |
| Difference  |                | S     |           | 5 -       | 5 -       | 5 -       | 5 -       |

## Appendix 4: Cash Flow Forecast

| CONSOLIDATED STATEMENTS OF CASH FLOWS - U   |          |           | -        |          |           |           |
|---|----------|-----------|----------|----------|-----------|-----------|
|   | 2020A    | 2021E     | 2022E    | 2023E    | 2024E     | 2025E     |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance OPERATING ACTIVITIES | \$ 4,239 | \$ 16,181 | \$ 4,239 | \$ 6,241 | \$ 19,539 | \$ 33,103 |
| Net Earnings  | 13,103   | 12,599    | 13,258   | 13,635   | 13,914    | 14,198    |
| Depreciation, Depletion and Amortization  | 3,013    | 0         | 0        | 0        | 0         | 0         |
| Gain (Loss) on Extinguishment of Debt   | 0        | 0         | 0        | 0        | 0         | 0         |
| Share-based Payment Arrangement, Noncash Expense  | 558      | 0         | 0        | 0        | 0         | 0         |
| Deferred Income Tax Expense (Benefit)   | (596)    | 0         | 0        | 0        | 0         | 0         |
| Gain (Loss) on Disposition of Business (Sale of Assets)   | 7        | 0         | 0        | 0        | 0         | 0         |
| Goodwill and Indefinite-lived Intangibles Impairment Charges Including Disc Ops                                 | 0        | 0         | 0        | 0        | 0         | .0        |
| Increase (Decrease) in Accounts Receivable  | 634      | (230)     | (198)    | (135)    | (100)     | (102)     |
| Increase (Decrease) in Inventories  | (637)    | (302)     | (261)    | (178)    | (132)     | (134)     |
| Increase (Decrease) in Accounts Payable and Accrued Liabilities   | 1,923    | 664       | 573      | 391      | 289       | 295       |
| Increase (Decrease) in Other Operating Assets and Liabilities, Net  | (710)    | 535       | 462      | 315      | 233       | 238       |
| Other Noncash Expense   | 108      | (117)     | (101)    | (69)     | (51)      | (52)      |
| Net Cash Provided by (Used in) Operating Activities   | 17,403   | 13,148    | 13,732   | 13,959   | 14,153    | 14,442    |
| INVESTING ACTIVITIES  |          |           |          |          |           |           |
| Payments to Acquire Property, Plant, and Equipment (CAPEX)  | (3,073)  | (1,195)   | (905)    | (661)    | (589)     | (561)     |
| Proceeds from Sale of Productive Assets   | 30       | 0         | 0        | 0        | 0         | 0         |
| Payments to Acquire Businesses, Net of Cash Acquired  | (58)     | 0         | 0        | 0        | 0         | 0         |
| Payments to Acquire Short-term Investments  | 0        | 0         | 0        | 0        | 0         | 0         |
| Proceeds from Sale of Short-term Investments  | 6,151    | 0         | 0        | 0        | 0         | 0         |
| Payments for (Proceeds from) Other Investments  | (5)      | 0         | 0        | 0        | 0         | 0         |
| Net Cash Provided by (Used in) Investing Activities   | 3,045    | (1,195)   | (905)    | (661)    | (589)     | (561)     |
| FINANCING ACTIVITIES  |          |           |          |          |           |           |
| Payments of Dividends to Shareholders   | (7,789)  | 0         | 0        | 0        | 0         | 0         |
| Proceeds from (Repayments of) Short-term Debt   | 2,345    | (11,183)  | 0        | 0        | 0         | 0         |
| Proceeds from Issuance of Long-term Debt (Additions to LT Debt)   | 4,951    | 0         | 0        | 0        | 0         | 0         |
| Repayments of Long-term Debt  | (2,447)  | (12,712)  | (10,825) | 0        | 0         | 0         |
| Payments for Repurchase of Common Stock (Treasury Stock Purchase)   | (7,405)  | 0         | 0        | 0        | 0         | 0         |
| Proceeds From Stock Options Exercised And Other Financing Activities  | 1,978    | 0         | 0        | 0        | 0         | 0         |
| Net Cash Provided by (Used in) Financing Activities   | (8,367)  | (23,895)  | (10,825) | 0        | 0         | 0         |
| EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH                                   | (139)    | 0         | 0        | 0        | .0        | 0         |
| CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH  | 11,942   | (11,942)  | 2,002    | 13,298   | 13,564    | 13,881    |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF YEAR   | 16,181   | 4,239     | 6,241    | 19,539   | 33,103    | 46,984    |
| Difference  | 0        | 0         | (0)      | (0)      | 0         | 0         |

## Appendix 5: Valuation

## P&G

| FREE CASH FLOWS - USD (\$) in Millions |          |        |        |        |        |  |
|--|----------|--------|--------|--------|--------|--|
| Discounted Cash Flow Model             | 2021E    | 2022E  | 2023E  | 2024E  | 2025E  |  |
| Operating Earnings                     | 16,570   | 17,315 | 17,825 | 18,201 | 18,585 |  |
| Less: Taxes                            | 25.97%   | 25.97% | 25.97% | 25.97% | 25.97% |  |
| Net Operating Profit After Taxes       | 12,267   | 12,819 | 13,196 | 13,475 | 13,759 |  |
| Less: CAPEX, Net                       | (1,195)  | (905)  | (661)  | (589)  | (561)  |  |
| Net Working Capital Changes            | 549      | 474    | 324    | 239    | 244    |  |
| Free Cash Flow                         | 11,621   | 12,389 | 12,859 | 13,125 | 13,442 |  |
| Weighted Average Cost of Capital       | 3.45%    |        |        |        |        |  |
| Net Present Value of Free Cash Flows   | \$57,231 |        |        |        |        |  |

|      | -      | We     | ighted Av | erage Cos | t of Capital |       |
|------|--------|--------|-----------|-----------|--------------|-------|
|      | 150.89 | 1.50%  | 2.50%     | 3.45%     | 4.50%        | 5.50% |
| Rate | 0.75%  | 674.85 | 280.55    | 176.62    | 122.90       | 93.88 |
| £    | 0.50%  | 507.37 | 246.04    | 161.99    | 115.44       | 89.35 |
| owt  | 0.28%  | 415.77 | 221.81    | 150.89    | 109.54       | 85.67 |
| ចុ   | 0.10%  | 363.81 | 205.78    | 143.13    | 105.28       | 82.97 |
| 5    | 0.05%  | 351.43 | 201.67    | 141.08    | 104.14       | 82.24 |

| Long-Term Growth           | Rate    |
|----------------------------|---------|
| Net Reinvestment           |         |
| CAPEX & Depreciation       | 561     |
| NWC Changes                | (244)   |
| Net Reinvestment           | 317     |
| NOPAT                      | 13,759  |
| Net Reinvestment Rate      | 2.31%   |
| Return on Invested Capital |         |
| NOPAT                      | 13,759  |
| Invested Capital           | 114,482 |
| ROIC                       | 12.02%  |
|                            |         |
|                            |         |

| Terminal Value                                     |         |
|--|---------|
| Numerator  | 14,042  |
| Denominator  | 3.17%   |
| Terminal Value                                     | 442,732 |
| Present Value of Terminal Value                    | 373,693 |
| Enterprise Value                                   | 430,924 |
| Less: Net Debt                                     | 34,720  |
| Add: Short-Term Investments                        | 1.9     |
| Equity Value                                       | 396,204 |
| Diluted Weighted Average Common Shares Outstanding | 2,626   |
| Value per Share                                    | 150.89  |
| Market Price, as at date of 10-K (06/30/2020)      | 117.46  |
| Market Price, as at March 31st 2021                | 135.45  |
| Undervalued, as at June 30, 2020                   | 28.46%  |
|  |         |

| Market Data           |         |  |  |
|-----------------------|---------|--|--|
| Price, as at 03/31/21 | 135.45  |  |  |
| Quarterly Dividend    | 0.7907  |  |  |
| Annual Dividend Yield | 2.34%   |  |  |
| Market Cap. (\$mm)    | 336,740 |  |  |
| P/E Ratio             | 26.4    |  |  |
| Beta                  | 0.39    |  |  |

| Buy                   |        |  |  |
|-----------------------|--------|--|--|
| Current Price         | 135.45 |  |  |
| 12-Month Target Price | 150.89 |  |  |
| Upside                | 11.40% |  |  |
| Dividend Yield        | 2.34%  |  |  |
| Total Return          | 13.73% |  |  |

## Appendix 6: Comparable Analysis

|                                     | C                       | OMPARABLE ANALYSIS - US  | SD (\$) \$ in Millions  |                            |                        |
|-------------------------------------|-------------------------|--------------------------|-------------------------|----------------------------|------------------------|
| EBITDA Multiple                     | Procter & Gamble (\$PG) | Colgate-Palmolive (\$CL) | Church & Dwight (\$CHD) | The Clorox Company (\$CLX) | Average (Excluding P&G |
| Market Price, as at Fiscal Year End | 117.46                  | 85.04                    | 86.96                   | 216.05                     | 129.3                  |
| Shares Outstanding                  | 2,486                   | 859                      | 252                     | 128                        | 413                    |
| Market Capitalization               | 292,016                 | 73,075                   | 21,931                  | 27,583                     | 40,863                 |
| Debt                                |                         |                          |                         |                            |                        |
| Short-Term                          | 11,183                  | 267                      | 351                     | 0                          | 206                    |
| Long-Term                           | 23,537                  | 7334                     | 1,813                   | 2780                       | 3,976                  |
| Total Debt                          | 34,720                  | 7,601                    | 2,164                   | 2,780                      | 4,182                  |
| Enterprise Value                    | 326,736                 | 80,676                   | 24,095                  | 30,363                     | 45,045                 |
| EBIT                                | 15,706                  | 3,885                    | 1,030                   | 1,284                      | 2,066                  |
| Depreciation & Amortization         | 3,013                   | 539                      | 190                     | 180                        | 303                    |
| EBITDA                              | 18,719                  | 4,424                    | 1,219                   | 1,464                      | 2,369                  |
| EBITDA Multiple                     | 17.45                   | 18.24                    | 19.76                   | 20.74                      | 19.58                  |
| Procter & Gamble (\$PG)             |                         | 4.014                    | 4000                    |                            | 2000                   |
| EBIT                                | 15,706                  | 15,706                   | 15,706                  | 15,706                     | 15,706                 |
| Depreciation & Amortization         | 3,013                   | 3,013                    | 3,013                   | 3,013                      | 3,013                  |
| EBITDA                              | 18,719                  | 18,719                   | 18,719                  | 18,719                     | 18,719                 |
| Enterprise Value                    | 326,736                 | 341,359                  | 369,885                 | 388,232                    | 366,492                |
| Less: Debt                          | 34,720                  | 34,720                   | 34,720                  | 34,720                     | 34,720                 |
| Equity Value                        | 292,016                 | 306,639                  | 335,165                 | 353,512                    | 331,772                |
| Shares Outstanding                  | 2,486                   | 2,486                    | 2,486                   | 2,486                      | 2,486                  |
| Value per Share                     | 117.46                  | 123.34                   | 134.82                  | 142.20                     | 133.45                 |
| Price, as at Fiscal YE              | 117.46                  | 117.46                   | 117.46                  | 117.46                     | 117.46                 |
| Under (Over) Valued (%)             | 0%                      | 5%                       | 15%                     | 21%                        | 14%                    |

| The Procter and Gamble, Co. Ratios |      |                   |        |                          |       |                               |       |                                  |        |                              |         |
|------------------------------------|------|-------------------|--------|--------------------------|-------|-------------------------------|-------|----------------------------------|--------|------------------------------|---------|
| Liquidity Ratios                   |      | Efficiency        |        | Financial Leverage       |       | Profitability                 |       | Growth and valuation             |        | Activity Ratio               |         |
| Cash ratio                         | 0.49 | Days receivables  | 21.49  | Debt to total assets     | 0.29  | Return on common equity (ROE) | 28.0% | One-year sales growth            | 4.6%   | Asset turnover               | 0.59    |
| Acid test (Quick ratio)            | 0.62 | Days payables     | 124.99 | Leverage Ratio           | 1.57  | Return on assets              | 8.6%  | One-year operating income growth | 65.1%  | Accounts receivable turnover | 16.98   |
| Current ratio                      | 0.85 | Days of inventory | 56.93  | Long-term leverage ratio | 0.50  | Return on invested capital    | 12.6% | One-year net income growth       | 69.73% | Inventory turnover           | 6.41    |
|                                    |      |                   |        | Debt to Equity           | 0.74  | Gross margin                  | 50.3% | Enterprise multiple              | 17.5   | Cash conversion cycle (days) | (46.57) |
|                                    |      |                   |        | Total debt to EBITDA     | 1.85  | EBITDA Margin                 | 26.4% | Enterprise value-to-sales        | 4.6    |                              |         |
|                                    |      |                   |        | Interest cover ratio     | 33.78 | Operating margin              | 22.1% | P/E ratio                        | 22.9   |                              |         |
|                                    |      |                   |        |                          |       | Pre-tax margin                | 22.3% |                                  |        |                              |         |
|                                    |      |                   |        |                          |       | Net income margin             | 18.5% |                                  |        |                              |         |

## Appendix 8: Additional Calculations

| The Procter a | and Gamble, Co. |
|---------------|-----------------|
| 5-Year M      | onthly Beta     |
| Covariance    | 0.00076890      |
| Variance      | 0.001949862     |
| Beta          | 0.39            |

| Cost of Equity                            | - 1   |
|---|-------|
| 10-Year Risk Free Rate (as of 03/31/2021) | 1.73% |
| Beta                                      | 0.39  |
| Market Risk Premium (Geometric Mean)      | 5%    |
| Cost of Equity                            | 3.70% |

| Cost of Debt                                 | -22    |
|--|--------|
| Cost of Debt                                 | 1.78%  |
| Effective Tax Rate (Averaged from 2018-2020) | 25.97% |
| After Tax Cost of Debt                       | 1.32%  |

| WACC                   |        |
|------------------------|--------|
| Cost of Equity         | 3.70%  |
| Weighted Equity        | 89.37% |
| After Tax Cost of Debt | 1.32%  |
| Weight of Debt         | 10.63% |
| WACC                   | 3.45%  |

| Enterprise Value            |        |              |  |  |  |
|-----------------------------|--------|--------------|--|--|--|
| Market Value of Equity      | 292,01 | 5,742,842.32 |  |  |  |
| Market Value of Debt        | 34     | ,720,000,000 |  |  |  |
| Enterprise Value            | 326,73 | 5,742,842.32 |  |  |  |
| Shares Outstanding          | 2      | ,486,086,692 |  |  |  |
| Market Price, June 30, 2020 | \$     | 117.46       |  |  |  |

| Capital Structure |        |  |  |  |
|-------------------|--------|--|--|--|
| Weight of Equity  | 89.37% |  |  |  |
| Weight of Debt    | 10.63% |  |  |  |


| Interest Rate Calculation (\$Millions)     |        |        |  |  |  |  |
|--|--------|--------|--|--|--|--|
|  | 2020   | 2019   |  |  |  |  |
| Total Debt                                 | 34,720 | 30,092 |  |  |  |  |
| Long-term Debt                             | 23,537 | 20,395 |  |  |  |  |
| Long-term weight average interest rates    | 2.30%  | 2.40%  |  |  |  |  |
| % of Debt                                  | 67.79% | 67.78% |  |  |  |  |
| Short-term Debt                            | 11,183 | 9,697  |  |  |  |  |
| Short-term weighted average interest rates | 0.70%  | 0.50%  |  |  |  |  |
| % of Debt                                  | 32.21% | 32.22% |  |  |  |  |
| Weighted Average Cost of Debt              | 1.78%  | 1.79%  |  |  |  |  |

<sup>\*</sup>Interest expense was \$465 million in fiscal 2020, a decrease of \$44 million versus the prior year due primarily to a reduction in U.S. interest rates, partially offset by an increase in debt.

# Appendix 9: Sensitivity Analysis

| Weighted Average Cost of Capital |        |        |        |        |        |       |  |  |
|----------------------------------|--------|--------|--------|--------|--------|-------|--|--|
|                                  | 150.89 | 1.50%  | 2.50%  | 3.45%  | 4.50%  | 5.50% |  |  |
| Rate                             | 0.75%  | 674.85 | 280.55 | 176.62 | 122.90 | 93.88 |  |  |
| th R                             | 0.50%  | 507.37 | 246.04 | 161.99 | 115.44 | 89.35 |  |  |
| owt                              | 0.28%  | 415.77 | 221.81 | 150.89 | 109.54 | 85.67 |  |  |
| ڣٙ                               | 0.10%  | 363.81 | 205.78 | 143.13 | 105.28 | 82.97 |  |  |
| 5                                | 0.05%  | 351.43 | 201.67 | 141.08 | 104.14 | 82.24 |  |  |





## Appendix 11: P&G Share Price History



## Appendix 12: 5-Year Shareholder Returns

